<DOC>
	<DOC>NCT00818168</DOC>
	<brief_summary>This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness of tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).</brief_summary>
	<brief_title>Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)</brief_title>
	<detailed_description>This study population was chosen from a non-probability sample.</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects with ankylosing spondylitis. As per Summary of Product Characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>